证券代码：000566 证券简称：海南海药 公告编号：2025-025 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：本次股东大会为2024年年度股东大会 2、股东大会的召集人：公司第十一届董事会。公司第十一届董事会第二十四次会 议于2025年4月10日审议通过了《关于召开2024年年度股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会的召开程序符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》等的规定。 4、会议召开的日期、时间： 现场会议召开时间：2025年5月9日下午15：00 网络投票时间：2025年5月9日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025年5月9日9：15～ 9：25，9：30～11：30和13：00～15：00； （2）通过深圳证券交易所互联网投票系统投票的时间为2025年5月9日9:15～ 15:00期间的任意时间。 海南海药股份有限公司 5、会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 公 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-024 海南海药股份有限公司 第十一届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）第十一届监事会第八次会议的会议通知 已于 2025 年 4 月 1 日以电子邮件等方式向全体监事发出。会议于 2025 年 4 月 10 日以现 场和视频相结合的方式召开。本次会议应参会监事 3 人，实际参会监事 3 人，其中张增 富先生以通讯表决方式出席本次会议，会议召开符合《公司法》《公司章程》的有关规定。 一、审议《关于2024年度监事会工作报告的议案》 表决结果：3 票同意、 0 票反对、0 票弃权 表决结果：3 票同意、 0 票反对、0 票弃权 《2024 年年度报告摘要》同日刊载于《上海证券报》《证券日报》及巨潮资讯网 （http://www.cninfo.com.cn）；《2024 年年度报告全文》同日刊载于巨潮资讯网 （http://www.cninfo.com.cn）。 此议案须提交 2024 年年度股东大会审议。 三、审议《关 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-023 海南海药股份有限公司 第十一届董事会第二十四次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）第十一届董事会第二十四次会 议于 2025 年 4 月 10 日以现场和视频相结合的方式召开。本次会议于 2025 年 4 月 1 日以电子邮件等通讯方式送达了会议通知及文件。会议应到董事 8 人，实到 董事 8 人，会议的召开符合《公司法》和《公司章程》有关规定。经与会董事认 真审议，表决通过了如下议案： 一、审议通过了《关于 2024 年度董事会工作报告的议案》 具体内容详见同日刊载于巨潮资讯网（http://www.cninfo.com.cn）的《2024 年年度报告》中的"第三节——管理层讨论与分析"和"第四节——公司治理之 六、报告期内董事履行职责的情况"。公司独立董事向董事会提交了《独立董事 2024 年度述职报告 》， 具 体 内 容 详 见 同 日 刊 载 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn ...

证券代码：000566 证券简称：海南海药 公告编号：2025-029 海南海药股份有限公司 关于 2024 年度利润分配的预案 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： | 归属于上市公司股 | - | | | | --- | --- | --- | --- | | 东的净利润（元） | 1,525,200,923.8 | -106,488,625.88 | 10,506,772.60 | | | 1 | | | | 合并报表本年度末 | | | | | 累计未分配利润 | | -3,629,126,228.15 | | | （元） | | | | | 母公司报表本年度 | | | | | 末累计未分配利润 | | -1,801,725,588.45 | | | （元） | | | | | 上市是否满三个 | | 是 | | | 完整会计年度 | | | | | 最近三个会计年度 | | | | | 累计现金分红总额 | | 0.00 | | | （元） | | | | | 最近三个会计年度 | | | | | 累计回购注销总额 | | 0. ...

前十大流通股东累计持有： 48886.75万股，累计占流通股比： 41.93%，较上期变化： -1080.33万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -1.1756 | -0.0821 | -1331.91 | 0.0081 | | 每股净资产（元） | 0.4 | 1.59 | -74.84 | 1.67 | | 每股公积金(元) | 2.16 | 2.16 | 0 | 2.16 | | 每股未分配利润(元) | -2.80 | -1.62 | -72.84 | -1.54 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 9.91 | 14.79 | -33 | 17.79 | | 净利润(亿元) | -15.25 | -1.06 | -1338.68 | 0.11 | | 净资产收益率(%) | -117.88 | -5.04 | -2238.89 | 0.49 | 数据 ...

海南海药（000566）公告，2024年营业收入为9.91亿元，同比下降33.00%。归属于上市公司股东的净亏 损15.25亿元，去年同期净亏损1.06亿元。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Financial Performance - The company's operating revenue for 2024 was CNY 990,701,458.53, a decrease of 33.00% compared to CNY 1,478,580,692.25 in 2023[21]. - The net profit attributable to shareholders for 2024 was a loss of CNY 1,525,200,923.81, compared to a loss of CNY 106,488,625.88 in 2023[21]. - The net cash flow from operating activities for 2024 was a negative CNY 17,552,031.29, down from a positive CNY 103,548,849.10 in 2023[21]. - The basic earnings per share for 2024 was -CNY 1.1756, compared to -CNY 0.0821 in 2023[21]. - The company's diluted earnings per share for 2024 is -1.1756 CNY, a significant decline from 0.0081 CNY in 2023[22]. - The weighted average return on equity for 2024 is -117.88%, down from 0.49% in 2023, indicating severe financial distress[22]. - Total assets decreased by 17.01% to 6,113,528,499.69 CNY in 2024 from 7,366,534,916.00 CNY in 2023[22]. - Net assets attributable to shareholders fell by 74.53% to 525,286,982.84 CNY in 2024 compared to 2,062,448,256.73 CNY in 2023[22]. - The company reported a total of -330,545,543.90 CNY in non-recurring losses for 2024, compared to 303,697,658.75 CNY in 2023[28]. - The company reported a net profit of -876,808,463.42 yuan for the 2024 fiscal year[152]. - The company reported an unallocated profit of -¥924,917,125.03, resulting in no profit available for distribution to shareholders[153]. Strategic Initiatives - Future outlook includes addressing operational risks and implementing measures to improve financial performance[5]. - The company is focusing on new product development and market expansion strategies to enhance growth prospects[5]. - The report indicates a need for strategic adjustments in response to declining revenues and profitability[21]. - The company aims to enhance its competitive edge by integrating resources and increasing R&D investment for new product development[51]. - The company is actively involved in the development of new drug intermediates, such as 7-ANCA and 4-AA, which are essential for the production of antibiotics like Cefoperazone and Meropenem[45]. - The company is focused on expanding its market reach through strategic partnerships and acquisitions in the pharmaceutical sector, aiming for growth in both domestic and international markets[46]. - The company is expanding its e-commerce business and leveraging the Hainan Free Trade Port policy to introduce foreign health products, aiming to increase market sales significantly[102]. - The company is currently fulfilling its commitments regarding competition and related transactions as per the acquisition report[187]. Research and Development - The company has accelerated its R&D efforts, achieving significant progress in product consistency evaluation, with 15 formulation products either approved or deemed approved[34]. - Research and development expenses amounted to ¥123,609,867.80, a decrease of 5.49% from ¥130,790,360.71 in the previous year[53]. - R&D investment amounted to ¥123,609,867.80 in 2024, a decrease of 5.49% from ¥130,790,360.71 in 2023, while the proportion of R&D investment to operating revenue increased from 8.85% to 12.48%[74]. - The company completed Phase II clinical trials for the anti-fibrosis drug Fluorofenidone, which is expected to expand the chronic disease drug pipeline[73]. - The company has a diverse pipeline with multiple drugs in various stages, including 5 drugs that have passed consistency evaluations and are awaiting market release[49]. Market and Sales Performance - The pharmaceutical segment generated ¥794,341,106.73, accounting for 80.18% of total revenue, reflecting a 38.06% decline from ¥1,282,384,086.12 in the previous year[54]. - Domestic sales amounted to ¥930,914,486, reflecting a significant year-on-year growth of 36.90%[57]. - The distribution business generated ¥536,383,638, up 53.83% compared to the previous year[57]. - The total sales volume of pharmaceutical products decreased by 36.47% to 114,557,690.02 units, primarily due to policy changes and reduced demand[58]. - The company achieved a 19.38% year-on-year increase in warehouse revenue, with overall warehouse utilization at 62% and cold storage utilization at 100%[38]. Governance and Compliance - The company emphasizes the importance of maintaining accurate financial reporting and compliance with regulatory standards[5]. - The company has established a high-level R&D team and optimized its talent structure, with 26 high-level talents recognized by Hainan Province[39]. - The company has established an EHS management system to comply with national safety and environmental regulations, aiming for sustainable development[106]. - The company has implemented a value enhancement plan and is committed to improving its governance structure in accordance with relevant laws and regulations[110]. - The company has not encountered any significant internal control deficiencies during the reporting period[156]. Environmental Responsibility - The company has complied with environmental protection policies and standards, ensuring that wastewater and waste gas emissions meet regulatory requirements[163]. - The company has invested significantly in environmental protection, ensuring that all pollutants are discharged within the standard limits, with no exceedances reported[175]. - The company conducts daily self-monitoring of wastewater parameters, including pH, COD, and ammonia nitrogen, with all results meeting the required limits[176]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental authority[178]. - The company has maintained a zero-incident record for environmental violations and pollutant exceedances throughout the reporting period[175]. Leadership and Management Changes - The company has a management team with a mix of experienced and newly appointed members, ensuring continuity and fresh perspectives[120]. - The company is preparing for future growth with a refreshed leadership team and strategic appointments[121]. - The company held its first temporary shareholders' meeting on April 2, 2024, with a participation rate of 32.37%[117]. - The company plans to hold its third temporary shareholders' meeting on December 18, 2024, with a participation rate of 31.81% expected[117]. - The company is focused on maintaining stability in its leadership as it approaches the next fiscal year[120].

创新药概念震荡拉升，海南海药（000566）涨停，一品红（300723）、泓博医药（301230）、科兴制 药、海正药业（600267）、中源协和（600645）等跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

截至本公告披露日，上述辞职人员未持有公司股份。王建鹏先生在任职期间 勤勉尽责，公司及董事会对王建鹏先生在任职期间为公司所作的贡献表示衷心感 谢。 证券代码：000566 证券简称：海南海药 公告编号：2025-022 海南海药股份有限公司 关于公司高级管理人员辞职的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"或"海南海药"）董事会于 2025 年 4 月 7 日收到王建鹏先生的辞职报告。王建鹏先生因工作调整的原因申请 辞去公司销售总监职务。辞职后，王建鹏先生仍在海南海药股份有限公司子公司 继续担任其他职务，其辞职报告自送达公司董事会之日起生效。 特此公告 海南海药股份有限公司 董 事 会 二〇二五年四月八日 ...

Core Viewpoint - The board of directors of Hainan Haiyao Co., Ltd. held a meeting on March 27, 2025, to discuss and approve several key resolutions, including the election of a new non-independent director, the appointment of a new general manager, and the provision of guarantees for subsidiaries [1][2][3]. Group 1: Board Resolutions - The board approved the election of Tian Yong as a non-independent director, following the retirement of Wang Junhong due to retirement [1][2]. - Tian Yong was also appointed as the general manager of the company, with his term starting from the board's approval [2]. - The board agreed to provide guarantees for its subsidiaries, with a total guarantee amount of 174 million yuan, to support their operational needs [2][3]. Group 2: Upcoming Shareholder Meeting - The board resolved to convene the second extraordinary general meeting of shareholders on April 16, 2025, to review the matters discussed in the board meeting [3]. Group 3: Candidate Profile - Tian Yong, born in 1981, graduated from China Pharmaceutical University in 2003 and has held various positions in Tianjin Huajin Pharmaceutical Co., Ltd. before joining Hainan Haiyao [4][5]. - He currently does not hold any shares in the company and has no conflicts of interest with major shareholders or other board members [5].